Zobrazeno 1 - 10
of 16
pro vyhledávání: '"Srinivasa BJ"'
Publikováno v:
Advances in Breast Cancer Research. :107-119
Background: Treatment refractory metastatic breast cancer patients are at best treated palliatively. We evaluated the effects of metronomic chemotherapy on survival outcomes in this population. Methods: Twenty eight subjects with treatment refractory
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::b20421f06af1afdee16f9e859415af0b
https://doi.org/10.4236/abcr.2018.72007
https://doi.org/10.4236/abcr.2018.72007
Autor:
Kulkarni, Vishal1,2 (AUTHOR) dr.vishalkulkarni@yahoo.co.in, Srinivasa, BJ2 (AUTHOR), Kiran, PK2 (AUTHOR), Sarathy, Vinu2 (AUTHOR), Swamy, S Shivakumar3 (AUTHOR), Naik, Radheshyam2 (AUTHOR)
Publikováno v:
Indian Journal of Medical & Paediatric Oncology. 2019 Supplement, Vol. 40, pS133-S135. 3p.
Autor:
Passaro, Antonio, de Marinis, Filippo, Tu, Hai-Yan, Laktionov, Konstantin K., Feng, Jifeng, Poltoratskiy, Artem, Zhao, Jun, Tan, Eng Huat, Gottfried, Maya, Lee, Victor, Kowalski, Dariusz, Yang, Cheng Ta, Srinivasa, BJ, Clementi, Laura, Jalikop, Tejaswini, Huang, Dennis Chin Lun, Cseh, Agnieszka, Park, Keunchil, Wu, Yi-Long
Publikováno v:
Frontiers in Oncology; 7/9/2021, Vol. 11, p1-10, 10p
Publikováno v:
Journal of Pharmacogenomics & Pharmacoproteomics.
Pharmacogenetic studies on 5-FU have mostly focused on enzyme Dihydropyrimidine Dehydrogenase (DPD), which is a rate-limiting enzyme in uracil and thymine catabolic pathway. Its activity has been found to be highly variable in different populations a
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::38ab7bf0b23cabdab7f0f163ebe1837a
https://doi.org/10.4172/2153-0645.1000165
https://doi.org/10.4172/2153-0645.1000165
Publikováno v:
Journal of Pharmacogenomics & Pharmacoproteomics.
Background: Regorafenib is an oral diphenyl urea multikinase inhibitor which is anti- angiogenic, and has shown promising anti-tumor activity in Metastatic Colorectal Cancer (mCRC). Reports have shown that response to regorafenib is more favourable i
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::1104a85fb03700290976b7acbb4f15fc
https://doi.org/10.4172/2153-0645.1000173
https://doi.org/10.4172/2153-0645.1000173
Publikováno v:
Journal of Case Reports. 3:130-133
Primary rhabdomyosarcoma (RMS) of breast and RMS, metastatic to breast are rare entities with limited case reports in literature. Here, we report a case of primary rhabdomyosarcoma of breast in an adolescent girl which was metastatic at presentation.
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::494d21982d47b76435a7ce1faee0f395
https://doi.org/10.17659/01.2013.0032
https://doi.org/10.17659/01.2013.0032
Autor:
Girish V Badarkhe, Viveka Belathur Kalegowda, Sulav Sapkota, Srinivasa Bj, Mohamed Musheb, Tousif T, Radheshyam Nayak, Shruthy Kodad, Bhanu Prakash Lalkota, Basavalinga S. Ajaikumar, P S Sridhar, Mansi Khanderia
Publikováno v:
Journal of Clinical Oncology. 34:e12569-e12569
e12569Background: We evaluated the effects of metronomic chemo (MC) on survival outcomes in refractory MBC population. Methods: 28 subjects with treatment refractory (21) and treatment naive (7) MB...
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::be02bd3d56e83c76d09cf516eb8fa6bb
https://doi.org/10.1200/jco.2016.34.15_suppl.e12569
https://doi.org/10.1200/jco.2016.34.15_suppl.e12569
Publikováno v:
Indian Journal of Surgical Oncology; Sep2017, Vol. 8 Issue 3, p433-435, 3p
Autor:
Lalkota BP; Department of Translational Medicine and Therapeutics, HCG Cancer Speciality Center, Bangalore, India., Srinivasa BJ; Department of Medical Oncology, HCG Cancer Speciality Center, Bangalore, India., Swamy MV; Center for Academics and Research, HCG Foundation, Bangalore, India., Hazarika D; Department of Translational Medicine and Therapeutics, HCG Cancer Speciality Center, Bangalore, India., Jeet BM; Department of Translational Medicine and Therapeutics, HCG Cancer Speciality Center, Bangalore, India., Jyothi K; Department of Translational Medicine and Therapeutics, HCG Cancer Speciality Center, Bangalore, India., Ghosh M; Department of Molecular Pathology, HCG Cancer Speciality Center, Bangalore, India., Sayeed SM; Department of Translational Medicine and Therapeutics, HCG Cancer Speciality Center, Bangalore, India., Nasiruddin M; Department of Molecular Pathology, HCG Cancer Speciality Center, Bangalore, India., Naik R; Department of Translational Medicine and Therapeutics, HCG Cancer Speciality Center, Bangalore, India.
Publikováno v:
Journal of cancer research and therapeutics [J Cancer Res Ther] 2023 Jan-Mar; Vol. 19 (2), pp. 208-213.
Autor:
Srinivasa BJ; Department of Medical Oncology, HCG-SC, Bengaluru, Karnataka, India., Sridhar PS; Department of Radiation Oncology, HCG-SC, Bengaluru, Karnataka, India., Lalkota BP; Department of Medical Oncology, HCG-SC, Bengaluru, Karnataka, India., Tsikai N; Department of Clinical Oncology, Harare Oncology Centre, Harare, Zimbabwe., Niyati PS; Department of Medical Oncology, HCG-SC, Bengaluru, Karnataka, India., Shah M; Department of Medical Oncology, HCG-SC, Bengaluru, Karnataka, India., Anuradha S; Department of Radiation Oncology, HCG-SC, Bengaluru, Karnataka, India., Roopesh R; Department of Radiation Oncology, HCG-SC, Bengaluru, Karnataka, India., Ramaswamy V; Department of Histopathology, HCG-SC, Bengaluru, Karnataka, India., Naik R; Department of Medical Oncology, HCG-SC, Bengaluru, Karnataka, India., Ajaikumar BS; Department of Radiation Oncology, HCG-SC, Bengaluru, Karnataka, India.
Publikováno v:
Journal of cancer research and therapeutics [J Cancer Res Ther] 2022 Dec; Vol. 18 (Supplement), pp. S495-S497.